Active Ingredient(s): Calaspargase Pegol-mknl
FDA Approved: * December 20, 2018
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Asparlas Overview

Calaspargase pegol, sold under the brand name Asparlas, is a medication for the treatment of acute lymphoblastic leukemia (ALL). It is approved in the United States as a component of a multi-agent chemotherapeutic regimen for ALL in pediatric and young adult patients aged one month to 21 years.[2] Calaspargase pegol is an engineered protein consisting of the E. coli-derived enzyme L-asparaginase II conjugated with succinimidyl carbonate monomethoxypolyethylene glycol (pegol)....

Read more Asparlas Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Asparlas Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Calaspargase Pegol-mknl
  • Injection: 3750units/5ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Asparlas: (1 result)

Sorted by National Drug Code
  • 72694-515 Asparlas 750 U/Ml Intravenous Injection, Solution by Servier Pharmaceuticals LLC

Other drugs which contain Calaspargase Pegol-mknl or a similar ingredient: (1 result)